eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2014
vol. 18
 
Share:
Share:
more
 
 
abstract:
Review paper

Actual status of therapeutic vaccination in non-small cell lung cancer

Katarzyna Szyszka-Barth, Katarzyna Ramlau, Joanna Goździk-Spychalska, Łukasz Spychalski, Maciej Bryl, Iwona Gołda-Gocka, Anna Kopczyńska, Aleksander Barinow-Wojewódzki, Rodryg Ramlau

Contemp Oncol (Pozn) 2014; 18 (2): 77–84
Online publish date: 2014/06/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Lung cancer is the leading cause of cancer-related death worldwide. Although treatment methods such as surgery, radiotherapy and/or chemotherapy have improved, prognosis remains unsatisfactory, and developing new therapeutic strategies is still an urgent matter. Immunotherapy is a novel therapeutic approach wherein activated immune cells can specifically kill tumour cells. Several lung cancer vaccines have demonstrated prolonged survival time in phase II and III trials, and several clinical trials are under investigation. However, many clinical trials involving cancer vaccination with defined tumour antigens have shown this method to work only in a small number of patients. Cancer immunotherapy is not completely effective in eradicating tumour cells because they evade host immune control.
keywords:

non-small cell lung cancer, immunotherapy, vaccines

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe